View in EDS

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

Saved in:
Bibliographic Details
Title: Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
Authors: Moreau, Philippe1 philippe.moreau@chu-nantes.fr, Pylypenko, Halyna2, Grosicki, Sebastian3, Karamanesht, Ievgenii4, Leleu, Xavier5, Grishunina, Maria6, Rekhtman, Grigoriy7, Masliak, Zvenyslava8, Robak, Tadeusz9, Shubina, Anna10, Arnulf, Bertrand11, Kropff, Martin12, Cavet, James13, Esseltine, Dixie-Lee14, Feng, Huaibao15, Girgis, Suzette15, van de Velde, Helgi16, Deraedt, William16, Harousseau, Jean-Luc17
Source: Lancet Oncology. May2011, Vol. 12 Issue 5, p431-440. 10p.
Database: Academic Search Ultimate
Description
ISSN:14702045
DOI:10.1016/S1470-2045(11)70081-X